In a recent article in IPT magazine, Synpromics’ founder and Chief Scientific Officer Dr. Michael L Roberts discusses the current obstacles to overcome in optimising gene therapies.
Synpromics collaborates with UCL to generate a range of synthetic gene promoters for the CNS to develop a gene therapy for Parkinson’s disease.
Synpromics Ltd, the leader in gene control, is listed by The Scotsman as one of the top 5 leading innovative companies in life sciences in Scotland.
In a recent blog by SynbiCITE, the UK’s national centre for the commercialisation of synthetic biology, Synpromics is listed as one of 7 prominent players in the UK’s thriving synthetic biology sector .
Synpromics have been awarded Best Emerging UK Synthetic Biotech Company at the 2017 OBN Awards for enabling safer, more effective cell and gene medicines.